Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
==== Addiction ==== Drug addiction is a complex set of behaviors typically associated with misuse of certain drugs, developing over time and with higher drug dosages. Addiction includes psychological compulsion, to the extent that the affected person persists in actions leading to dangerous or unhealthy outcomes. Opioid addiction includes insufflation or injection, rather than taking opioids orally as prescribed for medical reasons. In European nations such as Austria, Bulgaria, and Slovakia, slow-release oral morphine formulations are used in opiate substitution therapy (OST) for patients who do not well tolerate the side effects of buprenorphine or methadone. Buprenorphine can also be used together with naloxone for a longer treatment of addiction. In other European countries including the UK, this is also legally used for OST although on a varying scale of acceptance. Slow-release formulations of medications are intended to curb misuse and lower addiction rates while trying to still provide legitimate pain relief and ease of use to pain patients. Questions remain, however, about the efficacy and safety of these types of preparations. Further tamper resistant medications are currently under consideration with trials for market approval by the FDA. The amount of evidence available only permits making a weak conclusion, but it suggests that a physician properly managing opioid use in patients with no history of substance use disorder can give long-term pain relief with little risk of developing addiction, or other serious side effects.
== Medical uses == Cipaglucosidase alfa is a long-term enzyme replacement therapy used in combination with the enzyme stabilizer miglustat for the treatment of adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency).
A vocal lobby of anti-trans actors as part of the anti-gender movement attempt to spread misinformation regarding transgender health care, attempting to influence governments and the public and to deny legal recognition of transgender and gender diverse people and access to gender-affirming health care. The United Nations Independent Expert on sexual orientation and gender identity published the IESOGI Reports on Gender: The Law of Inclusion & Practices of Exclusion in 2021 that was presented at the 47th UN Human Rights Council and 76th UN General Assembly which highlighted laws violating the Universal Declaration of Human Rights and called out a series of alleged threats perpetuated by anti-trans actors in the spread of misinformation around transgender people's rights and related health care. This misinformation has resulted in some countries passing laws violating people's basic human rights such as denying legal gender recognition and restrictions on access to gender-affirming treatments, particularly for transgender youth who are being restricted from access to hormone treatments such as puberty blockers.
Sources: en.wikipedia.org
4-Fluoroselegiline, or p-fluoro-L-deprenyl, is a substituted amphetamine designer drug. It is the enantiopure L- enantiomer of 4-fluorodeprenyl and the 4-fluorinated derivative of selegiline (L-deprenyl).
Beta decay does not change the number (A) of nucleons in the nucleus, but changes only its charge Z. Thus the set of all nuclides with the same A can be introduced; these isobaric nuclides may turn into each other via beta decay. For a given A there is one that is most stable. It is said to be beta stable, because it presents a local minimum of the mass excess: if such a nucleus has (A, Z) numbers, the neighbour nuclei (A, Z−1) and (A, Z+1) have higher mass excess and can beta decay into (A, Z), but not vice versa. For all odd mass numbers A, there is only one known beta-stable isobar. For even A, there are up to three different beta-stable isobars experimentally known; for example, 12450Sn, 12452Te, and 12454Xe are all beta-stable. There are about 350 known beta-decay stable nuclides.
== Prognosis == Prognosis of spontaneous cervical arterial dissection involves neurological and arterial results. The overall functional prognosis of individuals with stroke due to cervical artery dissection does not appear to vary from that of young people with stroke due to other causes. The rate of survival with good outcome (a modified Rankin score of 0–2) is generally about 75%, or possibly slightly better (85.7%) if antiplatelet drugs are used. In studies of anticoagulants and aspirin, the combined mortality with either treatment is 1.8–2.1%. After the initial episode, 2% may experience a further episode within the first month. After this, there is a 1% annual risk of recurrence. Those with high blood pressure and dissections in multiple arteries may have a higher risk of recurrence. Further episodes of cervical artery dissection are more common in those who are younger, have a family history of cervical artery dissection, or have a diagnosis of Ehlers-Danlos syndrome or fibromuscular dysplasia.
== Biological activity == Protolichesterinic acid exhibits diverse biological activities, including antimicrobial, enzyme inhibitory, and anticancer properties. Studies with the compound isolated from Usnea albopunctata have demonstrated broad-spectrum antimicrobial activity. It shows strong antibacterial effects against Klebsiella pneumoniae (minimum inhibitory concentration 0.25 μg/mL) and Vibrio cholerae (0.5 μg/mL), exceeding the potency of ciprofloxacin. The compound is also active against methicillin-resistant Staphylococcus aureus (MRSA) and shows notable antifungal activity against Trichophyton rubrum, surpassing amphotericin B in potency. As an inhibitor, protolichesterinic acid selectively targets 5-lipoxygenase while showing minimal effect on cyclooxygenase. This selective inhibition suggests potential applications in treating inflammatory conditions, particularly those involving leukotriene bronchoconstrictors. Structure-activity studies indicate that while the stereospecific side chain and exocyclic double bond are not essential for activity, the carboxylic acid group plays a crucial role. The compound also inhibits the DNA polymerase activity of human immunodeficiency virus-1 reverse transcriptase (HIV-1 RT). Research has revealed that protolichesterinic acid affects cancer cell metabolism by disrupting mitochondrial function through inhibition of oxidative phosphorylation and enhancement of glycolysis. The compound undergoes cellular processing via the mercapturic pathway, forming conjugates with glutathione.
Sources: en.wikipedia.org
== Examples in thin layer chromatography == The chromatographic response functions in thin layer chromatography characterize the equal-spreading of the spots. The ideal case, when the retardation factor (RF) of the spots are uniformly distributed in [0,1] range (for example 0.25, 0.5 and 0.75 for three solutes) should be characterized as the best situation possible. The simplest criteria are ΔRF and ΔRF product. They are the smallest difference between sorted retardation factor values, or the product of such differences. Another function is the multispot response function (MRF) as developed by De Spiegeleer et al. It is based also of differences product. This function always lies between 0 and 1. When two RF values are equal, it is equal to 0, when all RF values are equal-spread, it is equal to 1. The L and U values – upper and lower limit of RF – give possibility to avoid the band region.
==== Positional effects ==== Although plants produce numerous copies of the same organ during their lives, not all copies of a particular organ will be identical. There is variation among the parts of a mature plant resulting from the relative position where the organ is produced. For example, along a new branch the leaves may vary in a consistent pattern along the branch. The form of leaves produced near the base of the branch will differ from leaves produced at the tip of the plant, and this difference is consistent from branch to branch on a given plant and in a given species. This difference persists after the leaves at both ends of the branch have matured, and is not the result of some leaves being younger than others.
Bodies having the power to regulate. In the ICH GCP guidance, the expression "Regulatory Authorities" includes the authorities that review submitted clinical data and those that conduct inspections. These bodies are sometimes referred to as competent authorities. (ICH E6) Retrospective
== Clinical significance == Truncation mutations in MYBPC3 stand as the primary cause of hypertrophic cardiomyopathy (HCM). To date, roughly 350 mutations in MYBPC3 have been identified, and in large part, the mutations result in protein truncation, shifts in reading frames, and premature termination codons. Genetic studies have revealed significant overlap between genotypes and phenotypes as MYBPC3 mutations can lead to various forms of cardiomyopathies, such as dilated cardiomyopathy and left ventricular noncompaction cardiomyopathy. In patients with isolated or familial cases of dilated cardiomyopathy, MYBPC3 mutations represented the second highest number of known mutations. Furthermore, a 25-bp intronic MYBPC3 deletion leading to protein truncation is present in 4% of the population in South India and is associated with a higher risk to develop heart failure. Founder MYBPC3 mutations have been reported in Iceland, Italy, The Netherlands, Japan, France and Finland, where they represent a large percentage of cases with hypertrophic cardiomyopathy. All of them are truncating mutations, resulting in a shorter protein, lacking the regulatory phosphorylatable M motif and/or major binding domains to other sarcomeric proteins. A body of evidence indicates that patients with more than one mutation often develop a more severe phenotype, and a significant fraction of childhood-onset hypertrophic cardiomyopathy (14%) is caused by compound genetic variants. This suggests that a gene-dosage effect might be responsible for manifestations at a younger age.
distillation The process of separating the component substances of a liquid mixture by exploiting differences in the relative volatility of the mixture's components through selective boiling and subsequent condensation. The apparatus used to distill a substance is called a still, and the re-condensed substance yielded by the process is called the distillate.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.